anti-HER2 therapydisitamab vedotingastric cancertrastuzumab deruxtecanT-DXd
…lly targetable entity, expanding the population benefiting from anti-HER2 therapy by 2-3-fold. This advancement underscores the imperative to red…
1articles mentioning treatments
1treatment mentions
1distinct treatments extracted
0%of mentions human-reviewed
Active filtersEntity: anti-HER2 therapy ×
anti-HER2 therapy
This treatment is selected. Its supporting articles are shown below.